OBJECTIVE: Lesch-Nyhan disease (LND) is caused by congenital deficiency of the purine recycling enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGprt). Affected patients have a peculiar neurobehavioral syndrome linked with reductions of dopamine in the basal ganglia. The purpose of the current studies was to determine the anatomical basis for the reduced dopamine in human brain specimens collected at autopsy. METHODS: Histopathological studies were conducted using autopsy tissue from 5 LND cases and 6 controls. Specific findings were replicated in brain tissue from an HGprt-deficient knockout mouse using immunoblots, and in a cell model of HGprt deficiency by flow-activated cell sorting (FACS). RESULTS: Extensive histological studies of the LND brains revealed no signs suggestive of a degenerative process or other consistent abnormalities in any brain region. However, neurons of the substantia nigra from the LND cases showed reduced melanization and reduced immunoreactivity for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis. In the HGprt-deficient mouse model, immunohistochemical stains for TH revealed no obvious loss of midbrain dopamine neurons, but quantitative immunoblots revealed reduced TH expression in the striatum. Finally, 10 independent HGprt-deficient mouse MN9D neuroblastoma lines showed no signs of impaired viability, but FACS revealed significantly reduced TH immunoreactivity compared to the control parent line. INTERPRETATION: These results reveal an unusual phenomenon in which the neurochemical phenotype of dopaminergic neurons is not linked with a degenerative process. They suggest an important relationship between purine recycling pathways and the neurochemical integrity of the dopaminergic phenotype.
OBJECTIVE:Lesch-Nyhan disease (LND) is caused by congenital deficiency of the purine recycling enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGprt). Affected patients have a peculiar neurobehavioral syndrome linked with reductions of dopamine in the basal ganglia. The purpose of the current studies was to determine the anatomical basis for the reduced dopamine in human brain specimens collected at autopsy. METHODS: Histopathological studies were conducted using autopsy tissue from 5 LND cases and 6 controls. Specific findings were replicated in brain tissue from an HGprt-deficient knockout mouse using immunoblots, and in a cell model of HGprt deficiency by flow-activated cell sorting (FACS). RESULTS: Extensive histological studies of the LND brains revealed no signs suggestive of a degenerative process or other consistent abnormalities in any brain region. However, neurons of the substantia nigra from the LND cases showed reduced melanization and reduced immunoreactivity for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis. In the HGprt-deficient mouse model, immunohistochemical stains for TH revealed no obvious loss of midbrain dopamine neurons, but quantitative immunoblots revealed reduced TH expression in the striatum. Finally, 10 independent HGprt-deficient mouseMN9Dneuroblastoma lines showed no signs of impaired viability, but FACS revealed significantly reduced TH immunoreactivity compared to the control parent line. INTERPRETATION: These results reveal an unusual phenomenon in which the neurochemical phenotype of dopaminergic neurons is not linked with a degenerative process. They suggest an important relationship between purine recycling pathways and the neurochemical integrity of the dopaminergic phenotype.
Authors: David J Schretlen; Mark Varvaris; Tiffany E Ho; Tracy D Vannorsdall; Barry Gordon; James C Harris; H A Jinnah Journal: Lancet Neurol Date: 2013-12 Impact factor: 44.182
Authors: Irene Ceballos-Picot; Lionel Mockel; Marie-Claude Potier; Luce Dauphinot; Thomas L Shirley; Raoul Torero-Ibad; Julia Fuchs; H A Jinnah Journal: Hum Mol Genet Date: 2009-04-02 Impact factor: 6.150
Authors: Maria G Zizzo; Monica Frinchi; Domenico Nuzzo; Hyder A Jinnah; Giuseppa Mudò; Daniele F Condorelli; Francesco Caciagli; Renata Ciccarelli; Patrizia Di Iorio; Flavia Mulè; Natale Belluardo; Rosa Serio Journal: Auton Neurosci Date: 2017-12-20 Impact factor: 3.145
Authors: Helena Biasibetti; Paula Pierozan; André Felipe Rodrigues; Vanusa Manfredini; Angela T S Wyse Journal: Mol Neurobiol Date: 2016-03-24 Impact factor: 5.590
Authors: J E Visser; S M Kolk; J S Witteveen; S R Loopstok; L Luque Ballesteros; A Boonstra; N H M van Bakel; W H P van Boekel; G J M Martens Journal: Cell Mol Life Sci Date: 2022-06-04 Impact factor: 9.207
Authors: Victor A Del Bene; Jeffrey L Crawford; Ainara Gómez-Gastiasoro; Tracy D Vannorsdall; Alison Buchholz; Natalia Ojeda; James C Harris; Hyder A Jinnah; David J Schretlen Journal: Eur J Neurosci Date: 2021-12-06 Impact factor: 3.698
Authors: Eric B Dammer; Martin Göttle; Duc M Duong; John Hanfelt; Nicholas T Seyfried; H A Jinnah Journal: Mol Genet Metab Date: 2015-03-05 Impact factor: 4.797
Authors: Scott Bell; Vincent McCarty; Huashan Peng; Malvin Jefri; Nuwan Hettige; Lilit Antonyan; Liam Crapper; Liam A O'Leary; Xin Zhang; Ying Zhang; Hanrong Wu; Diane Sutcliffe; Ilaria Kolobova; Thad A Rosenberger; Luc Moquin; Alain Gratton; Jelena Popic; Ilse Gantois; Patrick S Stumpf; Andreas A Schuppert; Naguib Mechawar; Nahum Sonenberg; Michel L Tremblay; Hyder A Jinnah; Carl Ernst Journal: Stem Cell Reports Date: 2021-07-01 Impact factor: 7.765